We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Countdown to Baxter (BAX) Q4 Earnings: Wall Street Forecasts for Key Metrics
Read MoreHide Full Article
Analysts on Wall Street project that Baxter International (BAX - Free Report) will announce quarterly earnings of $0.86 per share in its forthcoming report, representing a decline of 2.3% year over year. Revenues are projected to reach $3.8 billion, declining 2.3% from the same quarter last year.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
That said, let's delve into the average estimates of some Baxter metrics that Wall Street analysts commonly model and monitor.
Analysts' assessment points toward 'Sales- Acute Therapies' reaching $197.72 million. The estimate points to a change of +8.6% from the year-ago quarter.
The average prediction of analysts places 'Sales- Pharmaceuticals' at $568.78 million. The estimate points to a change of +3% from the year-ago quarter.
The combined assessment of analysts suggests that 'Sales- Front Line Care' will likely reach $316.16 million. The estimate indicates a change of +7.9% from the prior-year quarter.
Analysts forecast 'Sales- Other' to reach $15.59 million. The estimate points to a change of -57.9% from the year-ago quarter.
It is projected by analysts that the 'Sales- Acute Therapies- U.S.' will reach $66.50 million. The estimate indicates a change of +7.3% from the prior-year quarter.
Analysts expect 'Sales- Acute Therapies- International' to come in at $131.22 million. The estimate indicates a year-over-year change of +9.4%.
Based on the collective assessment of analysts, 'Sales- Pharmaceuticals- U.S.' should arrive at $191.67 million. The estimate points to a change of +2% from the year-ago quarter.
According to the collective judgment of analysts, 'Sales- Pharmaceuticals- International' should come in at $381.24 million. The estimate indicates a change of +4.7% from the prior-year quarter.
The consensus among analysts is that 'Sales- Advanced Surgery- U.S.' will reach $139.37 million. The estimate suggests a change of -4.5% year over year.
The collective assessment of analysts points to an estimated 'Geographic Sales- International' of $1.99 billion. The estimate indicates a change of -2% from the prior-year quarter.
Analysts predict that the 'Sales- Other- U.S.' will reach $9.36 million. The estimate indicates a year-over-year change of -66.6%.
The consensus estimate for 'Sales- Other- International' stands at $6.23 million. The estimate suggests a change of -30.8% year over year.
Shares of Baxter have demonstrated returns of -0.5% over the past month compared to the Zacks S&P 500 composite's +4.6% change. With a Zacks Rank #4 (Sell), BAX is expected to lag the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Countdown to Baxter (BAX) Q4 Earnings: Wall Street Forecasts for Key Metrics
Analysts on Wall Street project that Baxter International (BAX - Free Report) will announce quarterly earnings of $0.86 per share in its forthcoming report, representing a decline of 2.3% year over year. Revenues are projected to reach $3.8 billion, declining 2.3% from the same quarter last year.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
That said, let's delve into the average estimates of some Baxter metrics that Wall Street analysts commonly model and monitor.
Analysts' assessment points toward 'Sales- Acute Therapies' reaching $197.72 million. The estimate points to a change of +8.6% from the year-ago quarter.
The average prediction of analysts places 'Sales- Pharmaceuticals' at $568.78 million. The estimate points to a change of +3% from the year-ago quarter.
The combined assessment of analysts suggests that 'Sales- Front Line Care' will likely reach $316.16 million. The estimate indicates a change of +7.9% from the prior-year quarter.
Analysts forecast 'Sales- Other' to reach $15.59 million. The estimate points to a change of -57.9% from the year-ago quarter.
It is projected by analysts that the 'Sales- Acute Therapies- U.S.' will reach $66.50 million. The estimate indicates a change of +7.3% from the prior-year quarter.
Analysts expect 'Sales- Acute Therapies- International' to come in at $131.22 million. The estimate indicates a year-over-year change of +9.4%.
Based on the collective assessment of analysts, 'Sales- Pharmaceuticals- U.S.' should arrive at $191.67 million. The estimate points to a change of +2% from the year-ago quarter.
According to the collective judgment of analysts, 'Sales- Pharmaceuticals- International' should come in at $381.24 million. The estimate indicates a change of +4.7% from the prior-year quarter.
The consensus among analysts is that 'Sales- Advanced Surgery- U.S.' will reach $139.37 million. The estimate suggests a change of -4.5% year over year.
The collective assessment of analysts points to an estimated 'Geographic Sales- International' of $1.99 billion. The estimate indicates a change of -2% from the prior-year quarter.
Analysts predict that the 'Sales- Other- U.S.' will reach $9.36 million. The estimate indicates a year-over-year change of -66.6%.
The consensus estimate for 'Sales- Other- International' stands at $6.23 million. The estimate suggests a change of -30.8% year over year.
View all Key Company Metrics for Baxter here>>>
Shares of Baxter have demonstrated returns of -0.5% over the past month compared to the Zacks S&P 500 composite's +4.6% change. With a Zacks Rank #4 (Sell), BAX is expected to lag the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>